Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Vor Biopharma Inc. (VOR)
Company Research
Source: GlobeNewswire
First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. “Over the past six months, Vor Bio repositioned the company around telitacicept and moved quickly to build momentum. We are seeing strong engagement from key opinion leaders and principal investigators, which is critical as we advance the global development of telitacicept. In the first quarter, we initiated our global Phase 3 trial in primary Sjogren’s
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vor Biopharma (VOR) had its price target raised by Wedbush from $9.00 to $15.00. They now have a "neutral" rating on the stock.MarketBeat
- Vor Biopharma (VOR) was upgraded by Jefferies Financial Group Inc. to "strong-buy".MarketBeat
- Vor Biopharma (VOR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.MarketBeat
- Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s DiseaseGlobeNewswire
VOR
Earnings
- 3/30/26 - Miss
VOR
Sec Filings
- 4/1/26 - Form SCHEDULE
- 4/1/26 - Form 3
- 4/1/26 - Form SCHEDULE
- VOR's page on the SEC website